Loading asset research
Polaryx Therapeutics Inc. Common Stock
PLYXNasdaq · USD · StocksQuote as of · Exchange session not verified$2.01
+1.01%
Today
PLYX
Loading 1D prices…
Market cap
$100.2M
Volume
14.5K
52w high
$48.9152w low
$1.85Company profile
Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Paramus, NJ, United States
Employees
2
Fiscal year end
1231
CIK
2075320
Session & valuation
Open$2.00
Previous close$1.99
Day high$2.09
Day low$2.00
30-day avg. volume92K
Outstanding shares49.8M
Diluted EPS-$0.20
Latest annual period
P/E (trailing)-10.05
P/E (forward)—
Price / book9.18
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| COYACoya Therapeutics Inc. Common Stock | $102.7M | $7.9M | -267.14% | -$1.27 | -3.10% | Buy |
| CTORCitius Oncology Inc. Common Stock | $97M | $7.1M | -577.99% | -$0.42 | +0.88% | Buy |
| ANIXAnixa Biosciences Inc. Common Stock | $95.9M | $0.00 | — | -$0.23 | +1.82% | Buy |
| CPIXCumberland Pharmaceuticals Inc. Common Stock | $95.7M | $44.5M | -6.37% | -$0.19 | -1.39% | Unrated |
| BGMBGM Group Ltd. Class A Ordinary Shares | $105.4M | $37.9M | -52.59% | -$0.18 | -4.71% | Unrated |